Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of TQB2930 plus investigator-selected chemotherapy versus trastuzumab plus investigator-selected chemotherapy in HER2-positive advanced breast cancer
CTR20252567Phase 3Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of TQB2930, trastuzumab, capecitabine, gemcitabine, vinorelbine in breast cancer, sponsored by Nanjing Shunxin Pharmaceutical. Started Jul 2025; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20252567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252567.